Featured Research

from universities, journals, and other organizations

Lower-income patients fare better than wealthier after knee replacement

Date:
November 11, 2012
Source:
Mayo Clinic
Summary:
Patients who make $35,000 a year or less report better outcomes after knee replacement surgery than people who earn more, research shows.

Patients who make $35,000 a year or less report better outcomes after knee replacement surgery than people who earn more, research by Mayo Clinic and the University of Alabama at Birmingham shows. The lower-income patients studied reported less pain and better knee function at their two-year checkups than wealthier people did.

The study was being presented at the American College of Rheumatology annual meeting in Washington.

The finding is important as physicians try to figure out why some patients do better than others after knee replacement, says David Lewallen, M.D., an orthopedic surgeon at Mayo Clinic in Rochester, Minn., who conducted the study with Jasvinder Singh, M.D., of the University of Alabama at Birmingham.

"It runs counter to what many might have expected to see," Dr. Lewallen says. "We need to work to understand it further."

One possible explanation: Many lower-income patients delay knee replacement as long as possible, so their knees tend to be in worse shape and their feeling of improvement after the procedure more dramatic, he says.

Drs. Lewallen and Singh used the Mayo Clinic Total Joint Registry to assess the association of income with knee function and moderate to severe pain as reported by patients at follow-up appointments after knee replacement. The registry has data on nearly all of the 100,000 joint replacements at Mayo Clinic since it performed the first FDA-approved total hip replacement roughly 43 years ago. The researchers adjusted for other factors previously found to be linked to patient-reported outcomes after knee replacement, such as age, gender, body mass index and underlying diagnosis.

They found that those making $35,000 or less rated their overall improvement in knee function "better" more often at their two-year follow-ups than those who earned more, and also were less likely to report moderate to severe pain. The finding means that all other things being equal, a low income doesn't necessarily mean a patient will see poorer results from knee replacement, Dr. Lewallen says.

"This is one small piece of a very large puzzle in understanding patient outcomes following a well-defined surgery that we know is very effective for most," Dr. Lewallen says.

Total knee replacement is among the procedures that patients rate most highly as improving their quality of life, along with total hip replacement and cataract surgery, he says.


Story Source:

The above story is based on materials provided by Mayo Clinic. Note: Materials may be edited for content and length.


Cite This Page:

Mayo Clinic. "Lower-income patients fare better than wealthier after knee replacement." ScienceDaily. ScienceDaily, 11 November 2012. <www.sciencedaily.com/releases/2012/11/121111153608.htm>.
Mayo Clinic. (2012, November 11). Lower-income patients fare better than wealthier after knee replacement. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2012/11/121111153608.htm
Mayo Clinic. "Lower-income patients fare better than wealthier after knee replacement." ScienceDaily. www.sciencedaily.com/releases/2012/11/121111153608.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins